ROS1 L2026M

CI-VAR-00002307Explore in graph →NP_002935.2:p.Leu2026MetNM_002944.2:c.6076C>ACIViC 516

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma4
ROS1 L2026M AND CD74::ROS1 Fusion	Crizotinib	Predictive	D	Supports Resistance	2	accepted	EID1252 Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cel… (full text at CIViC) PMID 25733882 · Zou et al., 2015 · Open in CIViC	civic
ROS1 L2026M AND CD74::ROS1 Fusion	Crizotinib	Predictive	D	Supports Resistance	2	accepted	EID1257 Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74–ROS1; however, showed similar sensitivity t… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.